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Abstract
Background: The Anti-Clot Treatment Scale (ACTS) is a 15-item patient-reported instrument of satisfaction with
anticoagulant treatment. It includes a 12-item ACTS Burdens scale and a 3-item ACTS Benefits scale. Its role in
clinical trials and other settings should be supported by evidence that it is both clinically meaningful and
scientifically sound. The aim of the study was to evaluate the measurement performance of the ACTS (Dutch,
Italian, French, German and English language versions) in patients with venous thromboembolism based on
traditional psychometric methods.
Methods: ACTS Burdens and Benefits scale data from a large clinical trial (EINSTEIN DVT) involving 1336 people
with venous thromboembolism were analysed at both the scale and item level. Five key psychometric properties
were examined using traditional psychometric methods: acceptability, scaling assumptions, reliability (including
internal consistency reliability, test-retest reproducibility); validity (including known groups and discriminant validity);
and responsiveness. These methods of examination underpin the US Food and Drug Administration
recommendations for patient-reported outcome instrument evaluation.
Results: Overall, the 12-item ACTS Burdens scale and 3-item ACTS Benefits scale met the psychometric criteria
evaluated at both item and scale levels, with the exception of some relatively minor issues in the Dutch language
version, which were just below reliability criteria (i.e. alpha = 0.72, test-retest intraclass correlation = 0.79). A
consistent finding from item-level evaluations of aggregate endorsement frequencies and skewness suggested that
response scales may be improved by reducing the number of response options from five to four.
Conclusions: Both the ACTS Burdens and ACTS Benefits scales consistently satisfied traditional reliability and validity
criteria across multiple language datasets, supporting it as a clinically useful patient-reported instrument of
satisfaction with anticoagulant treatment in clinical trials.
Trial registration number: NCT00440193
Keywords: PRO instruments, Rating scales, Reliability, Validity, Venous thromboembolism
Background
Patient-reported outcome (PRO) instruments are rapidly
becoming the primary or secondary outcome measures
of choice in pivotal clinical trials, research and practice
[1], which means that PRO data now have a key role in
patient care, policy-making and prescribing. The quality
of inferences made from clinical trials is dependent on
the PRO instruments used, and thus they need to be sci-
entifically robust and clinically meaningful [2]. This is
increasingly acknowledged [3,4] and has led the US Food
and Drug Administration (FDA) to produce guidelines
[5] that specify minimum criteria for the scientific ad-
equacy of scales in clinical trials.
Venous thromboembolism (VTE) encompassing deep
vein thrombosis (DVT) and pulmonary embolism (PE)
occurs with an incidence rate of 1 to 2 per 1000 persons
per annum in Western countries, with two-thirds of
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cases presenting with DVT [6]. VTE can be idiopathic in
nature or be associated with risk factors such as surgery,
limb trauma or cancer [7]. Oral anticoagulant therapy
with vitamin K antagonists (VKAs), alongside initial par-
enteral heparin, have proved effective in the secondary
prevention of recurrent VTE [8,9]. However, VKA treat-
ment involves regular monitoring and dose adjustment,
owing to a narrow therapeutic window and an inherent
variability arising from genetic and dietary factors. This
can be challenging for the patient with the potential to
limit long-term persistence and adherence. In addition,
bleeding is an important side-effect of anticoagulation.
Therefore, as new anticoagulant therapies become
available, it will be essential to measure not only their ef-
fectiveness and safety in improving clinical outcomes,
but also their effectiveness in improving patient
satisfaction [10,11].
The Anti-Clot Treatment Scale (ACTS) is a 15-item
patient-reported instrument of satisfaction with anti-
coagulant treatment. It includes a 12-item ACTS Bur-
dens scale and a 3-item ACTS Benefits scale. The ACTS
also includes two additional global questions (see Ap-
pendix A). The ACTS was developed based on the ori-
ginal conceptual model of the Duke Anticoagulation
Satisfaction Scale (DASS) following a literature review,
interviews with experts and patients, and qualitative cog-
nitive debriefing interviews [10-12]. The original DASS
included 25 items covering the limitations, ‘hassles’ and
positive impacts related to anticoagulant treatment.
Modification of the DASS focused on making the instru-
ment more applicable to a wider range of respondents –
in particular, patients with DVT and PE and those in
different country settings. This was achieved through
qualitative research involving patient interviews and
consensus panels (further information is available from
the authors). The key changes included simplification of
the wording and structure of the original instrument,
improving item stems, changing the response timeframe,
reducing the response categories from 7 to 5, and
selecting the most relevant items for patients under-
going the different types of anticoagulant treatment. The
focus of the new instrument is to delineate the burdens
and benefits associated with anticoagulation therapy,
and is designed to be used in patients receiving long-
term anticoagulation irrespective of the underlying
condition.
If the ACTS is to be considered suitable for future
measurement of the burdens and benefits of anticoagu-
lation therapy in patients with VTE, it should satisfy
stringent criteria as a reliable and valid instrument. This
study provides clinical researchers with a comprehensive
evaluation of the reliability and validity of the ACTS
using traditional psychometric methods in line with
current guidelines.
Methods
Setting and participants
Bayer Pharma AG provided anonymised, blinded ACTS
Burdens and Benefits scale datasets from EINSTEIN
DVT, a large clinical trial involving patients with acute
symptomatic DVT treated with rivaroxaban or enoxa-
parin/VKAs [13]. The inclusion criteria included:
patients aged 18 years or older with a diagnosis of acute
symptomatic DVT without symptomatic PE. The
EINSTEIN DVT study included data from 1336 patients
across six time points (day 15, 1 month, 2 months,
3 months, 6 months and 12 months). The protocols
associated with the EINSTEIN trial programme were
approved by the institutional review board at each centre
and written informed consent was obtained from all
patients. For the current psychometric analysis reported
in this paper, the earliest time point data for each trial
was analysed (i.e. the first time that patients completed
the ACTS Burdens and Benefits scales; day 15).
Patients were asked to complete a questionnaire book-
let containing the ACTS and Treatment Satisfaction
Questionnaire for Medication version 2 (TSQM II) dur-
ing follow-up visits. The measurement performance of
the ACTS Burdens and Benefits scales was evaluated in
the following languages: Dutch, Italian, French, German
and English, and then a pooled dataset of all language
versions. In this paper, the scale-level analyses for the
separate study/language versions (acceptability, scaling
assumptions and reliability, including internal con-
sistency reliability, test-retest reproducibility) and both
item and scale-level analysis for the pooled language ver-
sions datasets (acceptability, scaling assumptions, reli-
ability [including internal consistency reliability]; validity
[including known groups and discriminant validity]; and
responsiveness) are presented. Further information is
available from the authors.
Instruments
The ACTS is a 15-item, patient-reported measure of
satisfaction with anticoagulant treatment. It includes
12 items that assess the burdens of anticoagulant treat-
ment and three items that assess the benefits of anti-
coagulant treatment. Patients are asked to rate their
experiences of anticoagulant treatment during the past
4 weeks on a 5-point scale of intensity (1 = not at all,
2 = a little, 3 = moderately, 4 = quite a bit, 5 = extremely).
The ACTS Burdens total score ranges from 12 to 60, and
the ACTS Benefits total score ranges from 3 to 15. When
used in clinical research, it is recommended that the ACTS
Burdens scores are reverse-scored so that higher ACTS
Burdens and Benefits scores indicate greater satisfaction
with treatment. For the purposes of this psychometric
evaluation, however, the original raw score data were ana-
lysed. French, Dutch, Italian, German and English language
Cano et al. Health and Quality of Life Outcomes 2012, 10:120 Page 2 of 11
http://www.hqlo.com/content/10/1/120
versions of the ACTS were created previously in accord-
ance with a standard protocol to achieve conceptual equiva-
lence in the translation, including: forward/backward
translation, reconciliation, review and pilot testing [14].
Further information about the translation process is avail-
able from the authors.
For validation purposes, the TSQM II was also
included. This is an 11-item PRO instrument that
assesses patient satisfaction with treatment. It includes
four scales: two items that assess the effectiveness
of treatment (TSQM II Effectiveness), three items that
assess side-effects (TSQM II Side-effects), three items
that assess convenience of treatment (TSQM II Con-
venience) and two items that assess global satisfaction
(TSQM II Global) [15]. Patients are asked to rate their
experiences of treatment between ‘extremely dissatisfied’
and ‘extremely satisfied’ on 5-point to 7-point scales.
Higher TSQM II scores indicate higher satisfaction with
treatment.
Data analysis
Psychometrics is a well-established scientific field that is
concerned with the measurement of subjective judge-
ments using numerical scales and the evaluation of the
measurement properties of such scales (e.g. reliability,
validity, responsiveness). The most widely used methods
for evaluating measurement performance are known as
‘traditional’ psychometric methods [16]. Traditional psy-
chometric methods form the basis for the recent FDA
guidelines [1,2,5] that specify minimum criteria for the
scientific adequacy of PRO instruments in clinical trials.
The methods and criteria selected for evaluating the psy-
chometric performance of the ACTS are grounded in
current widely accepted guidelines [3,4,17-20], including
the FDA guidance [5]. This methodology has been used
extensively in previous research to develop and validate
PRO instruments in other areas of medicine and surgery
[21-24].
Based on data collected, the following psychometric
properties of the ACTS were examined: acceptability (in-
cluding data quality and targeting); scaling assumptions;
internal consistency reliability and test-retest reproduci-
bility; aspects of validity (including known groups and
discriminant validity); and responsiveness. Table 1 sum-
marises the psychometric methods and criteria used in
this study to analyse and interpret results. Acceptability
and reliability analyses were carried out on the separate
language versions of the ACTS and the combined sam-
ple at baseline (N = 1336). Factor analysis and item con-
vergent/discriminant validity analysis were conducted on
the combined sample at baseline (N = 1336). Test-retest
reproducibility and construct validity examinations com-
paring the TSQM II were conducted on ACTS data from
a separate sub-sample of patients at 3 months (Burdens
scale, n = 792; Benefits scale, n = 822). Responsiveness
analysis was carried out on ACTS data from a separate
sub-sample of patients who completed the ACTS at
baseline and 3 months (Burdens scale, n = 1227; Benefits
scale, n = 1257).
Results
Sample
The EINSTEIN DVT ACTS validation dataset included
1336 patients (96% response rate) at day 15 (average age
was 57 years [standard deviation (SD) 16] and 42% were
female). Across each of the questionnaire language ver-
sions, this comprised: Dutch (n = 332; 55 years [SD= 15],
41% female); Italian (n = 217; 64 years [SD= 16], 41% fe-
male); French (n = 222; 57 years [SD= 18], 41% female);
German (n = 243; 56 years [SD= 15], 40% female); and
English (UK, US, Canada; n = 322; 54 years [SD= 15],
44% female). The pooled EINSTEIN DVT dataset, in-
cluding all language versions, comprised 1336 patients
(average age was 57 years [SD= 16] and 42% were
female). Overall, patients participating in the treatment
satisfaction sub-study had similar baseline character-
istics to the full EINSTEIN DVT trial population (a
full description of patient demographics is presented
elsewhere).
Psychometric properties: scale level by study/language
version (Dutch, Italian, French, German, English)
Acceptability: data quality and targeting
For each language version, there was a low level of miss-
ing data for all item and scale scores for both the ACTS
Burdens and ACTS Benefits (scale level <5%). This
means that scale scores could be computed for >95% of
patients. There was a reasonable distribution of ACTS
Burdens scores (mean 60%, range 54–77%), and an ex-
cellent distribution of ACTS Benefits scores (mean
100%). Floor and ceiling effects were generally low for
both scale scores (mean 5%, range 0–14%) and data
skewness was slightly higher for the ACTS Burdens
scores than for the ACTS Benefits scores (mean −1.02
[range −0.78 to −1.35] vs −0.84 [range −1.97 to 0.03], re-
spectively) (Table 2).
Reliability: internal consistency, test-retest and
homogeneity coefficients
Across EINSTEIN DVT datasets, Cronbach’s alpha
and test-retest intra-class correlations for both ACTS
Burdens and ACTS Benefits scores were acceptable
(>0.82), with the exception of the Dutch version (alpha =
0.79; test-retest = 0.72). The homogeneity coefficient
mean ranged from 0.24 to 0.75 (Table 2).
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Psychometric properties: item and scale level by
combined language versions (EINSTEIN DVT pooled
language datasets)
Acceptability: data quality and targeting
There were minimal missing data for all item and scale
scores (<4%). Therefore, scale scores could be computed
for >96% of patients, which was slightly higher than the
individual country analysis owing to the effect of pooling
the datasets. At the scale level, there was a good distri-
bution of ACTS Burdens scores (77%) and an excellent
distribution of ACTS Benefits scores (100%). Scale-level
floor and ceiling effects were generally low for both scale
scores (range 0–11%). Data skewness was slightly higher
for the ACTS Burdens scale scores than for the ACTS
Table 1 Summary of psychometric methods
Psychometric property Definition/criteria for acceptability
Acceptability Assessed by data quality and targeting. Data quality refers to the completeness of item- and scale-level data.
Assessed by completeness of data; criterion for missing data <10% [20]. Targeting is the extent to which the
range of the variable measured by a scale matches the range of that variable in the study sample. Assessed
by: maximum endorsement frequencies <80% [17], aggregate endorsement frequenciesa >10% [17], and
skewness statistic −1 to +1 [35-37], proximity of scale mean score to scale midpointb (no fixed criterion but
closer matches indicated better targeting) [38], and acceptable distribution of ACTS Burdens scoresc (no
fixed criterion but closer to 100% indicates better targeting) [39]
Scaling assumptions Tests of scaling assumptions assess the extent to which it is legitimate to sum a set of items, without
weighting or standardisation, to produce a single total score. This criterion is satisfied when items have
adequate corrected-item total correlations≥0.30 [38,40] and the proposed grouping of items in each
subscale is correct. Assessed by using two complementary approaches: principal components analysis
(factor loadings >0.30, cross-loadings <0.20) and item convergent and discriminant validity (item own-scale
correlations >0.30, magnitude >2 standard errors than other scales)
Reliability Reliability is the extent to which scale scores are not associated with random error
Internal consistency reliability The precision of the scale based on the homogeneity (intercorrelations) of items at a single point in time.
Assessed using Cronbach’s alpha≥0.80 [41,42], mean item-item correlations (known as the homogeneity
coefficient)≥0.30 [37] and item-total correlations≥0.30 [42]
Test-retest reproducibility This is based on the agreement between people scores at screening and baseline, and estimates the ability
of components and scales to produce stable scores [34]. For adequate test-retest reproducibility, scale-level
intraclass correlation coefficients ≥0.80 [40] and item-level intraclass correlation coefficients ≥0.50 [43]
should be achieved
Validity Validity is the extent to which a scale measures the construct that it is intended to measure
Validity (within scale) Evidence that a scale measures a single construct, and that items can be combined to form a summary
score. Assessed on the basis of internal consistency reliability (Cronbach’s alpha≥ 0.80) and factor analysis
(factor loadings >0.30, cross-loadings < 0.20)
Validity (correlations between scales) Correlations between ACTS scales: moderate correlations (0.30–0.70) expected. Correlations between
TSQM IId [44] and ACTS scales: low correlations (< 0.30) expected between TSQM II Effectiveness and ACTS
Burdens/ACTS Benefits; low correlations (< 0.30) expected between TSQM II Side-effects and ACTS Benefits;
moderate correlations (0.30–0.70) expected between TSQM II Side-effects and ACTS Burdens; moderate
correlations (0.30–0.70) expected between TSQM II Convenience and ACTS Burdens/ACTS Benefits;
moderate correlations (0.30–0.70) expected between TSQM II Global Satisfaction and ACTS
Burdens/ACTS Benefits
Discriminant validity Evidence that a scale is not correlated with other measures of different constructs. Assessed on the basis
of correlations between the ACTS and age and gender; low correlations (<0.30) expected between ACTS
scores and age and gender
Known-groups validity/hypothesis testing Ability of a scale to detect hypothesised differences between known subgroups. Assessed by testing the
hypothesis that known groups defined on the basis of high vs low ACTS global scores for: i) Burdens (Q13)
and ii) Benefits (Q17) will differ significantly (in the expected direction) on ACTS Burdens and Benefits scale
scores; based on ANOVA (p < 0.05)
Responsiveness The ability of the ACTS Burden and Benefits scales to detect significant change over time, assessed by
examining scores at two or more time points of surgery and calculating an effect size statistic calculated as
the mean difference (change score) in scores at time point 1 to time point 2 divided by the standard
deviation of the time 1 score [44]. Clinically, increasing moderate effect sizes over time would be expected,
reflecting improved treatment satisfaction. Effect sizes were interpreted as the following: 0.20 (small
change), 0.50 (moderate change) and>0.80 (large change) [45]
aCalculated as the sum of responses between any two adjacent response categories (e.g. if responses to ‘not at all’= 2% and ‘a little’= 7%, aggregate endorsement
frequency = 9%, which fails the criterion).
bCalculated as possible scale midpoint minus actual scale mean score.
cCalculated as actual scale range divided by possible scale range multiplied by 100.
dTSQM II was designed as a general measure of treatment satisfaction with medication, and includes 11 items in 4 sub-scales (Effectiveness, Side-effects,
Convenience, Global Satisfaction).
ACTS Anti-Clot Treatment Scale, ANOVA analysis of variance, TSQM II Treatment Satisfaction Questionnaire for Medication version 2.
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Benefits scale scores (sk=−1.08 and sk=−0.80, respectively).
At the item level, the ACTS Burdens scale ceiling effects
ranged from 37% to 77%. In both datasets, in relation to ag-
gregate endorsement frequencies, for all items, three of five
response categories met the >10% criterion, but two of five
response categories were <10% (between response categor-
ies 4 and 5) and 10 of 12 items fell outside the skewness cri-
terion (−1, +1). The ACTS Benefits scale had much lower
ceiling effects, which ranged from 15% to 19%. In relation
to aggregate endorsement frequencies, for all items, three of
five response categories met the >10% criterion, but two of
five response categories were <10% (between response
categories 4 and 5) and all items passed the skewness cri-
terion (Table 3).
Psychometric properties: scaling assumptions
Item groupings in the ACTS Burdens and ACTS Bene-
fits scales passed tests for scaling assumptions.
Corrected-item total correlations for both scales ranged
from 0.39 to 0.80, satisfying the recommended criteria
(>0.30). This indicated that items in each scale measured
a common underlying construct and contained a similar
proportion of information. In addition, principal compo-
nents analysis factor loadings (>0.48) and tests of item
convergent/discriminant validity (>0.39) supported this
finding, thus further indicating that all items in each of
the scales passed the criteria (Tables 3, 4 and 5).
Psychometric properties: internal consistency reliability
Corrected-item total correlations (>0.39), Cronbach’s
alpha (>0.85) and test-retest intraclass correlations
(>0.86) for both scales in both datasets passed the cri-
teria, supporting their reliability (Table 3).
Psychometric properties: validity
Overall, the correlations with the four TSQM II scale
scores were consistent with predictions (4/4 correlations
meeting predictions; Table 6). Known groups validity
was supported for both the ACTS Burdens and ACTS
Benefits scale scores on the global items (p < 0.0001; fur-
ther information available from the authors). Discrimin-
ant validity correlations suggest no bias by age or sex
(r <−0.16).
Psychometric properties: responsiveness
The pattern of mean scores over time suggested a trend
to higher scores in the ACTS Burdens and ACTS Bene-
fits scales over the six time points assessed (day 15,
1 month, 2 months, 3 months, 6 months, and
12 months). Responsiveness statistics comparing day 15
scores with all the other time points individually
Table 2 ACTS Burdens and Benefits scales: scale-level data quality, scaling assumptions, targeting and reliability
Acceptability Targeting Reliability
Item
missing
data (%)a
Possible
range
(midpoint)
Actual
score
range
Mean
score
(SD)
Floor/ceiling
effects (%)b
Skewness Cronbach’s
alpha
Test-
retestc
Mean IICd Range IIC
EINSTEIN DVT dataset
Dutch version (n=332)
ACTS Burdens 4 12–60 (36) 34–60 53.4 (5.45) 0/10 –0.99 0.79 0.95 0.24 0.03–0.69
ACTS Benefits 1 3–15 (9) 3–15 10.5 (2.20) 1/3 −0.77 0.80 0.72 0.56 0.46–0.66
Italian version (n=217)
ACTS Burdens 4 12–60 (36) 33–60 52.4 (6.26) 0/12 −0.78 0.90 0.94 0.43 0.25–0.83
ACTS Benefits 1 3–15 (9) 3–15 10.7 (2.15) 1/8 0.03 0.90 0.94 0.75 0.68–0.79
French version (n=222)
ACTS Burdens 4 12–60 (36) 33–60 55.6 (4.97) 0/14 −1.35 0.89 0.95 0.40 0.23–0.70
ACTS Benefits 3 3–15 (9) 3–15 11.5 (2.40) 2/12 −0.89 0.86 0.76 0.68 0.60–0.72
German version (n=243)
ACTS Burdens 5 12–60 (36) 34–60 52.0 (5.91) 0/7 −0.86 0.84 0.98 0.29 0.04–0.86
ACTS Benefits 1 3–15 (9) 3–15 12.2 (2.15) 2/12 −1.97 0.82 0.91 0.60 0.56–0.67
English version (n=322)e
ACTS Burdens 0 12–60 (36) 23–60 51.6 (6.78) 0/7 −1.12 0.86 0.98 0.36 0.12–0.67
ACTS Benefits 0 3–15 (9) 3–15 11.4 (2.50) 1/14 −0.62 0.87 0.91 0.70 0.59–0.74
aLess than 0.5% missing data rounded to 0. bCalculated as the percentage of people scoring either 12 (floor) or 60 (ceiling) on the ACTS Burdens scale or 3 (floor)
or 15 (ceiling) on the ACTS Benefits scale. cTest-retest between two administrations at 12 weeks. dRepresenting homogeneity. eUK, US, Canada.
ACTS Anti-Clot Treatment Scale, IIC item-item correlation, SD standard deviation, VTE venous thromboembolism.
Cano et al. Health and Quality of Life Outcomes 2012, 10:120 Page 5 of 11
http://www.hqlo.com/content/10/1/120
supported a trend of increasingly higher ACTS Burdens
and Benefits scales scores over time, with low but in-
creasing effect size statistics (range −0.14 to −0.37 and
−0.03 to −0.33, respectively) (Table 7).
Discussion
Current PRO instrument guidelines [3-5] make it in-
creasingly important for clinical researchers to under-
stand the science behind the instruments used to try to
capture the patient perspective. In this study, both the
ACTS Burdens and ACTS Benefits scales satisfied trad-
itional psychometric criteria for data quality, scaling
assumptions, targeting, reliability, validity and respon-
siveness. In fact, its psychometric properties were found
to be remarkably stable across different cultural groups,
supporting pooling of data. This study, together with
previous work on conceptual model development
[10,11], provides an initial evidence base for its use in
clinical trials and other settings (e.g. post-market surveil-
lance, clinical research and in practice), in line with the
current FDA guidelines (Table 8). The ACTS can be
used to evaluate and compare different therapies in
patients with DVT [25], it is acceptable to patients, and
has a simple checklist format that can be completed eas-
ily and quickly. Importantly, the ACTS measures aspects
of treatment satisfaction, treatment adherence, relevance
(e.g. burdens surrounding treatment regimens, impact
on daily activities, and the possibility of bruising and
bleeding) and important positive outcomes to patients
(e.g. benefits surrounding assurance and confidence in
treatment) [11].
Overall, the 12-item ACTS Burdens and 3-item ACTS
Benefits scales met the psychometric criteria evaluated
at both item and scale levels. Item-level targeting was
Table 3 ACTS Burdens and Benefits scales - EINSTEIN DVT dataset (all countries): data quality, scaling assumptions,
targeting, reliability (N=1336)
Data quality Scaling assumptions Targeting Reliability
Item missing
data (%)a
Possible
range
(midpoint)
Actual
score
range
Mean
score
SD CITC Floor/ceiling
effects (%)b
Skewness Cronbach’s
alpha
Test-
retestc
Mean
IICd
Range
IIC
Burden items
Q1 Bleeding/vigorous
activities
1 1–5 1–5 4.26 1.03 0.50 3/57 −1.41 - - - -
Q2 Bleeding/usual
activities
1 1–5 1–5 4.47 0.86 0.50 1/65 −1.79 - - - -
Q3 Bruising 0 1–5 1–5 4.39 0.87 0.45 1/58 −1.49 - - - -
Q4 Avoid other
medicines
0 1–5 1–5 4.54 0.80 0.39 1/69 −1.84 - - - -
Q5 Limit eat/drink 0 1–5 1–5 4.55 0.78 0.46 1/69 −1.87 - - - -
Q6 Hassle/daily 0 1–5 1–5 4.41 0.78 0.60 0/56 −1.22 - - - -
Q7 Hassle/occasional 1 1–5 1–5 4.02 0.98 0.57 2/38 −0.85 - - - -
Q8 Difficult to follow
your ACT
0 1–5 1–5 4.71 0.58 0.52 0/77 −2.19 - - - -
Q9 Time-consuming
ACT
0 1–5 1–5 4.52 0.69 0.43 0/62 −1.40 - - - -
Q10 Worry about ACT 1 1–5 1–5 4.07 0.91 0.56 1/37 −0.84 - - - -
Q11 Frustrating ACT 0 1–5 1–5 4.45 0.87 0.61 1/64 −1.76 - - - -
Q12 Burden of ACT 1 1–5 1–5 4.49 0.75 0.65 0/62 −1.52 - - - -
ACTS Burdens scale 4 12–60 (36) 23–60 52.9 6.1 - 0/11 −1.08 0.85 0.97 0.32 0.13–0.66
Benefit items
Q14 Confident in ACT 1 1–5 1–5 3.77 0.91 0.71 3/19 −0.88 - - - -
Q15 Reassured by ACT 1 1–5 1–5 3.71 0.87 0.80 3/15 −0.84 - - - -
Q16 Satisfied with ACT 0 1–5 1–5 3.79 0.90 0.69 3/19 −0.92 - - - -
ACTS Benefits scale 1 3–15 (9) 3–15 11.3 2.4 - 1/10 −0.80 0.86 0.86 0.67 0.59–0.73
aLess than 0.5% missing data rounded to 0. bCalculated as the percentage of people scoring either 12 (floor) or 60 (ceiling) on the ACTS Burdens scale or 3 (floor)
or 15 (ceiling) on the ACTS Benefits scale. cTest-retest between two administrations at 12 weeks. dRepresenting homogeneity.
ACT anticoagulation treatment, ACTS Anti-Clot Treatment Scale, CITC corrected item-total correlation, IIC item-item correlation, SD standard deviation, - analyses
not conducted owing to lack of data.
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adequate given the nature of the target construct (i.e. a
scale that taps into aspects of treatment satisfaction
would be expected to result in a degree of skew to the
positive in score distributions) [26]. Scaling assumptions
were also broadly supported, as were criteria for internal
consistency reliability at item and scale level and scale-
level test-retest reproducibility. Validity was also sup-
ported by assessments of discriminant validity and
known-groups comparisons. Finally, responsiveness ana-
lyses supported increasing improvement over time in
both treatment satisfaction scores. Looking forward,
three areas require further consideration: construct val-
idity, response options and further exploration of
responsiveness.
First, construct validity analyses in the form of testing
hypothesised correlations between the ACTS Burdens
scale and four scales of the TSQM II were supported in
the pooled dataset but were slightly lower than expected.
This issue may reflect the fact that, although both measures
focus on treatment satisfaction, the constructs captured by
the ACTS and TSQM II are more distinct than would be
first expected. On closer inspection, the TSQM II items
that capture ‘Effectiveness’, ‘Side-effects’, ‘Convenience’
and ‘Global satisfaction’ are significantly different from
the ACTS Burdens and Benefits items. Thus, despite
some overlap between the two instruments, there are
key differences – for example, the TSQM II Effective-
ness scale has one of two items addressing symptom
alleviation, not directly impacted by anti-coagulation
or measured by ACTS. Furthermore, the TSQM II
Side-effects items do not directly address the import-
ant anticoagulation-specific side-effects of bleeding or
bruising, which are measured in ACTS Burdens items.
In addition, the TSQM II is more narrowly targeted at
the medicine, the ACTS being more inclusive of the
services and difficulties of undergoing anticoagulation
therapy. Thus, the findings from the analyses should
be interpreted with these facts in mind.
The second issue that requires further exploration is
that, across all language versions, findings from item-
level tests of aggregate endorsement frequencies and
skewness suggested that response scales may be
improved by reducing the number of response options
from five to four. This is also reflected in the findings
from the scale-level targeting, which also revealed
slightly skewed distributions across the board. One
Table 4 ACTS Burdens and Benefits scales – EINSTEIN
DVT datasets: principal components analysis with
VARIMAX rotation
Item EINSTEIN DVT (N=1336)
Component
1 2
ACTS Burdens
Q1 Bleeding/vigorous activities 0.58 −0.06
Q2 Bleeding/usual activities 0.57 0.03
Q3 Bruising 0.54 0.06
Q4 Avoid other medicines 0.48 0.07
Q5 Limit eat/drink 0.55 0.02
Q6 Hassle/daily 0.69 0.10
Q7 Hassle/occasional 0.66 0.08
Q8 Difficult to follow your ACT 0.62 0.11
Q9 Time-consuming ACT 0.53 0.12
Q10 Worry about ACT 0.65 0.11
Q11 Frustrating ACT 0.71 0.09
Q12 Burden of ACT 0.74 0.09
ACTS Benefits
Q14 Confident in ACT 0.03 0.88
Q15 Reassured by ACT 0.07 0.91
Q16 Satisfied with ACT 0.19 0.83
Extraction method: principal components analysis; rotation method: VARIMAX
with Kaiser normalization.
ACT anticoagulation treatment, ACTS Anti-Clot Treatment Scale.
Values refer to factor loadings on each component: Component 1 =ACTS
Burdens; Component 2 =ACTS Benefits.
Table 5 ACTS Burdens and Benefits scales – EINSTEIN
DVT dataset: item convergent/discriminant validity
Item EINSTEIN DVT (N=1336)
ACTS Burdens
scale
ACTS Benefits
scale
ACTS Burdens
Q1 Bleeding/vigorous activities 0.50 0.06
Q2 Bleeding/usual activities 0.50 0.14
Q3 Bruising 0.45 0.13
Q4 Avoid other medicines 0.39 0.12
Q5 Limit eat/drink 0.46 0.10
Q6 Hassle/daily 0.60 0.17
Q7 Hassle/occasional 0.57 0.15
Q8 Difficult to follow your ACT 0.52 0.16
Q9 Time-consuming ACT 0.43 0.15
Q10 Worry about ACT 0.56 0.18
Q11 Frustrating ACT 0.61 0.17
Q12 Burden of ACT 0.65 0.16
ACTS Benefits
Q14 Confident in ACT 0.13 0.71
Q15 Reassured by ACT 0.17 0.80
Q16 Satisfied with ACT 0.26 0.69
ACT anticoagulation treatment, ACTS Anti-Clot Treatment Scale.
Values refer to correlations of items to their own scale (corrected-item total
correlations) and other scales (Pearson’s r correlations).
Cano et al. Health and Quality of Life Outcomes 2012, 10:120 Page 7 of 11
http://www.hqlo.com/content/10/1/120
potential cause for this is that there may simply have
been too many response options for respondents to dis-
criminate between, especially at the more satisfied ex-
treme of the choices. This is not uncommon in PRO
instruments [27] and it has been found previously that
four categories work better than five [28]. Another possi-
bility is that the response category labelling is problem-
atic. The present findings uncovered a consistent issue
in the way in which patients responded in the ‘not at all’
and ‘a little’ categories. Therefore, a reconsideration of
wording in these response categories may also help to
improve measurement performance. However, given that
the current validation is limited to the five-option re-
sponse scale, this is a matter for consideration in future
development of the ACTS.
The responsiveness analyses, which can be considered
to be preliminary, revealed a modest but stepwise in-
crease in ACTS Burdens and Benefits scale scores over
the six time points. The associated responsiveness statis-
tics were moderate but were in the range that would be
expected clinically. This is because scale responsiveness
and treatment effectiveness are inseparably linked
[29,30]. The effect sizes computed on ACTS Burdens
and Benefits scale scores from day 15 to all other time
points are indicators of the ability of these scales to de-
tect change. However, these are also an indicator of the
size of the treatment effect. To put the present findings
in context, it may be useful to consider the effect sizes
of other interventions. Thus, effect sizes associated with
hip arthroplasty have been shown to be very large (3.1)
[31]. This would be expected given the dramatic impact
of this surgical intervention of pain symptomatology. By
contrast, the effect of carpal tunnel repair on grip
strength is small (0.2) [32]. A degree of improved treat-
ment satisfaction associated with anticoagulant treat-
ment would be expected to occur over time, but would
not be expected to be as marked as intensive interven-
tions. However, the clinical meaning of the ACTS Bur-
dens and Benefits scale change scores and specification
of what constitutes an important difference based on
these scores are matters for consideration in future de-
velopment of the ACTS. Given some of the potential
limitations of traditional responsiveness statistics [33],
further evaluations would be desirable using more
sophisticated modern rating scale analysis techniques
[34] to further delineate the specific ability of the ACTS
Burdens and Benefits to detect differences between and
clinically meaningful change within patients.
Our study has two key limitations. First, although the
scope of our psychometric evaluation of the ACTS in
patients being treated for acute DVT was relatively com-
prehensive, there are further analyses that would aid our
understanding of the measurement performance of the
ACTS Burdens and ACTS Benefits scales. These would
include further known groups and discriminant validity
tests based on clinically sensible sub-grouping (based on
predefined hypothesis-driven selection) and responsive-
ness analyses assessed against a priori clinically
anchored hypotheses. The second limitation is that the
Table 6 ACTS Burdens and Benefits scales – EINSTEIN
DVT dataset: construct validity correlations with TSQM II
subscales at 3 months
ACTS
Burdens
ACTS
Benefits
TSQEFF TSQSIDE TSQCON
ACTS Burdens 1.00
ACTS Benefits 0.33 1.00
TSQEFF 0.16 0.18 1.00
TSQSIDE 0.35 0.14 0.29 1.00
TSQCON 0.32 0.24 0.53 0.29 1.00
TSQGLO 0.32 0.27 0.53 0.36 0.74
ACTS Anti-Clot Treatment Scale, TSQCON TSQM II Convenience, TSQEFF TSQM II
Effectiveness, TSQGLO TSQM II Global Satisfaction, TSQSIDE, TSQM II Side-
effects.
Table 7 ACTS Burdens and Benefits scales – EINSTEIN DVT dataset (N=1336): responsiveness – mean change score,
t statistic, p-value and effect size for day 15 compared with all other time points
Mean SD t P ES
Pair 1 ACTS Burdens day 15 to ACTS Burdens month 1 −0.84 3.98 7.30 0.000 −0.14
Pair 2 ACTS Burdens day 15 to ACTS Burdens month 2 −1.25 4.75 8.95 0.000 −0.20
Pair 3 ACTS Burdens day 15 to ACTS Burdens month 3 −1.35 4.65 9.80 0.000 −0.22
Pair 4 ACTS Burdens day 15 to ACTS Burdens month 6 −1.65 4.88 10.39 0.000 −0.27
Pair 5 ACTS Burdens day 15 to ACTS Burdens month 12 −2.00 4.40 5.78 0.000 −0.37
Pair 1 ACTS Benefits day 15 to ACTS Benefits month 1 −0.06 2.22 −1.03 0.304 −0.03
Pair 2 ACTS Benefits day 15 to ACTS Benefits month 2 −0.16 2.45 −2.30 0.021 −0.07
Pair 3 ACTS Benefits day 15 to ACTS Benefits month 3 −0.18 2.46 −2.58 0.010 −0.08
Pair 4 ACTS Benefits day 15 to ACTS Benefits month 6 −0.29 2.49 −3.71 0.000 −0.12
Pair 5 ACTS Benefits day 15 to ACTS Benefits month 12 −0.77 2.60 −3.84 0.000 −0.33
ACTS Anti-Clot Treatment Scale, SD standard deviation.
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small size of the English-language versions (i.e. US, UK,
Canada) required that these be combined prior to psy-
chometric analyses. Further testing using adequate sam-
ples in each country would provide useful additional
evidence for the relative measurement performance of
the ACTS scales.
Conclusions
Overall, across the different language versions, evidence
from the psychometric evaluation of the ACTS in
patients treated for acute DVT supports the use of the
12-item ACTS Burdens scale and the 3-item ACTS Ben-
efits scale. The ACTS can provide essential information
about VTE-related treatment satisfaction from the
patient’s perspective. This new instrument will comple-
ment current clinical outcome measures and facilitate
multicentre studies for comparison of treatments and
patient populations. Thus, the ACTS has the potential
to support treatment trials, cost-effectiveness analysis
and patient education, providing crucial data for clinical
researchers, clinicians and patients. Further potential
psychometric research on the ACTS includes exploring
reducing the number of response options from five to
four, providing evidence that both ACTS Burdens and
Benefits scales are able to detect a clinically meaningful
change over time and exploring the potential of using
the scales in clinical practice settings.
Appendix A. Anti-Clot Treatment Scale
During the past 4 weeks. . .
1 How much does the possibility of bleeding as a
result of anti-clot treatment limit you from
taking part in vigorous physical activities?
(e.g. exercise, sports, dancing, etc.).
2 How much does the possibility of bleeding as a
result of anti-clot treatment limit you from taking
part in your usual activities? (e.g. work, shopping,
housework, etc.).
3 How bothered are you by the possibility of
bruising as a result of anti-clot treatment?
4 How bothered are you by having to avoid other
medicines (e.g. aspirin) as a result of anti-clot
treatment?
5 How much does anti-clot treatment limit your diet?
(e.g. food or drink, including alcohol).
6 How much of a hassle (inconvenience) are the
daily aspects of anti-clot treatment? (e.g.
Table 8 Adapted from Table 4 of the FDA guidelines for measurement properties reviewed for PRO instruments used
in clinical trials
Measurement property Test Methods used
in testing the
ACTS
Reliability Test-retest ✓
Internal consistency Whether the items in a domain are intercorrelated, as evidenced
by an internal consistency statistic (e.g., coefficient alpha)
✓
Inter-interviewer reproducibility (for interviewer-administered
PROs only)
Agreement between responses when the PRO is administered
by two or more different interviewers
NA
Validity Content-related ✓a
Ability to measure the concept (also known as construct-related
validity; can include tests for discriminant, convergent and
known-groups validity)
Whether relationships among items, domains and concepts
conform to what is predicted by the conceptual framework for
the PRO instrument itself and its validation hypotheses
✓
Ability to predict future outcomes (also known as predictive
validity)
Whether future events or status can be predicted by changes in
the PRO scores
x
Ability to detect change Includes calculations of effect size and standard error of
measurement among others
✓
Interpretability Smallest difference that is considered to be clinically important;
this can be a specified difference (the minimum important
difference) or, in some cases, any detectable difference. The
minimum important difference is used as a benchmark to
interpret mean score differences between treatment arms in a
clinical trial
✓b
Responder definition – used to identify responders in clinical
trials for analysing differences in the proportion of responders
between treatment arms
Change in score that would be clear evidence that an individual
patient experienced a treatment benefit. Can be based on
experience with the measure using a distribution-based
approach, a clinical or non-clinical anchor, an empirical rule, or a
combination of approaches
NA
aReported in Wild et al. 2009 [10]; bFurther additional information available from the authors.
✓=tested; x=not tested.
ACTS Anti-Clot Treatment Scale, FDA US Food and Drug Administration, NA not applicable, PRO patient-reported outcome.
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remembering to take your medicine at a certain
time, taking the correct dose of your medicine,
following a diet, limiting alcohol, etc.).
7 How much of a hassle (inconvenience) are the
occasional aspects of anti-clot treatment? (e.g. the
need for blood tests, going to or contacting the
clinic/doctor, making arrangements for treatment
while travelling, etc.).
Now I want to ask you about daily and occasional
aspects of your anticoagulation therapy during the past
4 weeks
8 How difficult is it to follow your anti-clot treatment?
9 How time-consuming is your anti-clot treatment?
10 How much do you worry about your anti-clot
treatment?
11 How frustrating is your anti-clot treatment?
12 How much of a burden is your anti-clot treatment?
13 Overall, how much of a negative impact has your
anti-clot treatment had on your life?
14 How confident are you that your anti-clot treatment
will protect your health? (e.g. prevent blood clots,
stroke, heart attack, DVT, embolism)
15 How reassured do you feel because of your anti-clot
treatment?
16 How satisfied are you with your anti-clot treatment?
17 Overall, how much of a positive impact has your
anti-clot treatment had on your life?
Abbreviations
ACTS: Anti-Clot Treatment Scale; DASS: Duke Anticoagulation Satisfaction
Scale; DVT: Deep vein thrombosis; FDA: US Food and Drug Administration;
PE: Pulmonary embolism; PRO: Patient-reported outcome; SD: Standard
deviation; TSQM II: Treatment Satisfaction Questionnaire for Medication
version 2; VKA: Vitamin K antagonist; VTE: Venous thromboembolism.
Competing interests
LB is an employee of Bayer Pharma AG. SC, DL and SS were supported in
part through a grant from Bayer Pharma AG.
Authors’ contributions
SC conducted, analysed and interpreted the data and wrote the manuscript.
DL was involved in guiding the study, including design and analysis of data.
LB and SS were involved in providing additional input and reviewing drafts
of this manuscript. All authors read and approved the final manuscript.
Copyright
Copyright of the ACTS instrument is held by Bayer AG, Germany (2006). All
rights reserved. For information on or permission to use, please contact Mapi
Research Trust; http://www.mapi-trust.org.
Acknowledgements
The study was supported by Bayer Pharma AG. The authors wish to
acknowledge the advice and input from Greg Samsa and Diane Wild
(together with her colleagues at Oxford Outcomes) during the early stages
of ACTS content development. Oxford Outcomes also co-ordinated the
translations of the ACTS scales. In addition, the authors would like to
acknowledge David Whitford, who provided editorial support with funding
from Bayer HealthCare Pharmaceuticals. The authors also wish to thank the
participating EINSTEIN Investigators and patients for their involvement in
this study.
Author details
1Department of Clinical Neuroscience, Peninsula College of Medicine and
Dentistry, Room N16 ITTC Building, Tamar Science Park, Davy Road,
Plymouth, Devon PL6 8BX, UK. 2Department of Health Services Research and
Policy, London School of Hygiene and Tropical Medicine, Keppel Street,
London WC1E 7HT, UK. 3Bayer Pharma AG, Wuppertal, Germany.
4Department of Health Services Research and Policy, London School of
Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK.
Received: 9 March 2012 Accepted: 10 September 2012
Published: 26 September 2012
References
1. Revicki DA: FDA draft guidance and health-outcomes research. Lancet
2007, 369:540–542.
2. Cano SJ, Hobart JC: Watch out, watch out, the FDA are about. Dev Med
Child Neurol 2008, 50:408–409.
3. Scientific Advisory Committee of the Medical Outcomes Trust: Assessing
health status and quality-of-life instruments: attributes and review
criteria. Qual Life Res 2002, 11:193–205.
4. Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL, Bouter
LM, de Vet HC: The COSMIN checklist for assessing the methodological
quality of studies on measurement properties of health status
measurement instruments: an international Delphi study. Qual Life Res
2010, 19:539–549.
5. Food and Drug Administration: Guidance for industry: Patient-reported
outcome measures: use in medical product development to support
labeling claims: draft guidance. Health Qual Life Outcomes 2006, 4:79.
6. Heit JA: Venous thromboembolism: disease burden, outcomes and risk
factors. J Thromb Haemost 2005, 3:1611–1617.
7. White RH: The epidemiology of venous thromboembolism. Circulation
2003, 107:14–18.
8. Petersen P: New approaches to anticoagulation in atrial fibrillation. Curr
Cardiol Rep 2004, 6:354–364.
9. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G: Pharmacology
and management of the vitamin K antagonists: American College of
Chest Physicians evidence-based clinical practice guidelines (8th
Edition). Chest 2008, 133:160S–198S.
10. Wild D, Murray M, Donatti C: Patient perspectives on taking vitamin K
antagonists: a qualitative study in the UK, USA and Spain. Expert Rev
Pharmacoecon Outcomes Res 2009, 9:467–474.
11. Wild D, Murray M, Shakespeare A, Reaney M, von Maltzahn R: Patient-
reported treatment satisfaction measures for long-term anticoagulant
therapy. Expert Rev Pharmacoecon Outcomes Res 2008,
8:291–299.
12. Samsa G, Matchar DB, Dolor RJ, Wiklund I, Hedner E, Wygant G, Hauch O,
Marple CB, Edwards R: A new instrument for measuring anticoagulation-
related quality of life: development and preliminary validation. Health
Qual Life Outcomes 2004, 2:22.
13. The EINSTEIN Investigators: Oral rivaroxaban for symptomatic venous
thromboembolism. N Engl J Med 2010, 363:2499–2510.
14. Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A, Erikson
P: Principles of good practice for the translation and cultural adaptation
process for patient-reported outcomes (PRO) measures: report of the
ISPOR Task Force for translation and cultural adaptation. Value Health
2005, 8:94–104.
15. Atkinson MJ, Kumar R, Cappelleri JC, Hass SL: Hierarchical construct validity
of the treatment satisfaction questionnaire for medication (TSQM
version II) among outpatient pharmacy consumers. Value Health 2005,
8(Suppl 1):S9–S24.
16. Novich M: The axioms and principal results of classical test theory. J Math
Psychol 1966, 3:1–18.
17. World Health Organization Quality of Life Group: The World Health
Organization Quality of Life Assessment (WHOQOL): development and
general psychometric properties. Soc Sci Med 1998, 46:1569–1585.
18. Streiner DL: Health Measurement Scales: A Practical Guide to Their
Development and Use. New York: Oxford University Press; 2008.
19. Ware JE, Harris WJ, Gandek B, Rogers BW, Reese PR: MAP-R for Windows:
Multitrait/Multi-Item Analysis Program—Revised User’s Guide. Boston, MA:
Health Assessment Lab; 1997.
Cano et al. Health and Quality of Life Outcomes 2012, 10:120 Page 10 of 11
http://www.hqlo.com/content/10/1/120
20. Ware JE Jr, Snow K, Kosinski M, Gandek B: Medical Outcome Short Form
Health Survey manual and interpretation guide.
http://www.clintools.com/victims/resources/assessment/health/SF36.pdf.
21. Cano SJ, Browne JP, Lamping DL, Roberts AH, McGrouther DA, Black NA:
The Patient Outcomes of Surgery-Hand/Arm (POS-Hand/Arm): a new
patient-based outcome measure. J Hand Surg Br 2004, 29:477–485.
22. Cano SJ, Warner TT, Thompson AJ, Bhatia KP, Fitzpatrick R, Hobart JC: The
cervical dystonia impact profile (CDIP-58): can a Rasch developed
patient reported outcome measure satisfy traditional psychometric
criteria? Health Qual Life Outcomes 2008, 6:58.
23. Lamping DL, Schroter S, Marquis P, Marrel A, Duprat-Lomon I, Sagnier PP:
The community-acquired pneumonia symptom questionnaire: a new,
patient-based outcome measure to evaluate symptoms in patients with
community-acquired pneumonia. Chest 2002, 122:920–929.
24. Lamping DL, Schroter S, Kurz X, Kahn SR, Abenhaim L: Evaluation of
outcomes in chronic venous disorders of the leg: development of a
scientifically rigorous, patient-reported measure of symptoms and
quality of life. J Vasc Surg 2003, 37:410–419.
25. Bamber L, Cano SJ, Lamping DL, Wang MY, Prins MH, Bauersachs R, Gallus
AS, Lensing AWA: Patient-reported treatment satisfaction with oral
rivaroxaban vs. standard therapy in the treatment of symptomatic deep
vein thrombosis (DVT). J Thromb Haemost 2011, 9:859. Abstract P-TH-284.
26. Sitzia J, Wood N: Patient satisfaction: a review of issues and concepts. Soc
Sci Med 1997, 45:1829–1843.
27. Cano SJ, Barrett LE, Zajicek JP, Hobart JC: Beyond the reach of traditional
analyses: using Rasch to evaluate the DASH in people with multiple
sclerosis. Mult Scler 2011, 17:214–222.
28. Hobart J, Cano S: Improving the evaluation of therapeutic interventions
in multiple sclerosis: the role of new psychometric methods. Health
Technol Assess 2009, 13:iii, ix–iii,177.
29. Cano SJ, O'Connor RJ, Thompson AJ, Hobart JC: Exploring disability rating
scale responsiveness II: do more response options help? Neurology 2006,
67:2056–2059.
30. O'Connor RJ, Cano SJ, Thompson AJ, Hobart JC: Exploring rating scale
responsiveness: does the total score reflect the sum of its parts?
Neurology 2004, 62:1842–1844.
31. Fitzpatrick R, Morris R, Hajat S, Reeves B, Murray DW, Hannen D, Rigge M,
Williams O, Gregg P: The value of short and simple measures to assess
outcomes for patients of total hip replacement surgery. Qual Health Care
2000, 9:146–150.
32. Dias JJ, Bhowal B, Wildin CJ, Thompson JR: Carpal tunnel decompression.
Is lengthening of the flexor retinaculum better than simple division? J
Hand Surg Br 2004, 29:269–274.
33. Hobart JC, Cano SJ, Thompson AJ: Effect sizes can be misleading: is it
time to change the way we measure change? J Neurol Neurosurg
Psychiatry 2010, 81:1044–1048.
34. Andrich D: Rating scales and Rasch measurement. Expert Rev
Pharmacoecon Outcomes Res 2011, 11:571–585.
35. Hays RD, Anderson R, Revicki D: Psychometric considerations in
evaluating health-related quality of life measures. Qual Life Res 1993,
2:441–449.
36. Holmes W, Bix B, Shea J: SF-20 score and item distributions in a human
immunodeficiency virus-seropositive sample. Med Care 1996,
34:562–569.
37. McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD: The MOS 36-item Short-
Form Health Survey (SF-36): III. Tests of data quality, scaling
assumptions, and reliability across diverse patient groups. Med Care 1994,
32:40–66.
38. Eisen M, Ware JE Jr, Donald CA, Brook RH: Measuring components of
children's health status. Med Care 1979, 17:902–921.
39. Brook RH, Ware JE Jr, Davies-Avery A, Stewart AL, Donald CA, Rogers WH,
Williams KN, Johnston SA: Overview of adult health measures fielded in
Rand's health insurance study. Med Care 1979, 17:iii–131.
40. Nunnally JC, Bernstein I: Psychometric Theory. New York: McGraw-Hill; 1994.
41. Cronbach L: Coefficient alpha and the internal structure of tests.
Psychometrika 1951, 16:297–334.
42. Stevens SS: Mathematics, Measurement, and Psychophysics. Handbook of
Experimental Psychology. Oxford: Wiley; 1951.
43. Duruoz MT, Poiraudeau S, Fermanian J, Menkes CJ, Amor B, Dougados M,
Revel M: Development and validation of a rheumatoid hand functional
disability scale that assesses functional handicap. J Rheumatol 1996,
23:1167–1172.
44. Cohen J: Statistical Power Analysis for the Behavioral Sciences. New York:
Academic Press; 1977.
45. Kazis LE, Anderson JJ, Meenan RF: Effect sizes for interpreting changes in
health status. Med Care 1989, 27:S178–S189.
doi:10.1186/1477-7525-10-120
Cite this article as: Cano et al.: The Anti-Clot Treatment Scale (ACTS) in
clinical trials: cross-cultural validation in venous thromboembolism
patients. Health and Quality of Life Outcomes 2012 10:120.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Cano et al. Health and Quality of Life Outcomes 2012, 10:120 Page 11 of 11
http://www.hqlo.com/content/10/1/120
